About Inflammatix
Inflammatix is a company based in San Francisco (United States) founded in 2016. Inflammatix has raised $191.47 million across 13 funding rounds from investors including NIH, Khosla Ventures and HHS. The company has 54 employees as of December 31, 2020. Inflammatix offers products and services including TriVerity Test and Host Response Dx. Inflammatix operates in a competitive market with competitors including Karius, MeMed, Visby Medical, Agendia and GenMark Diagnostics, among others.
- Headquarter San Francisco, United States
- Employees 54 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$191.47 M (USD)
in 13 rounds
-
Latest Funding Round
$57 M (USD), Series E
Sep 12, 2024
-
Investors
NIH
& 13 more
-
Employee Count
54
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inflammatix
Inflammatix offers a comprehensive portfolio of products and services, including TriVerity Test and Host Response Dx.
Analyzes immune responses to identify infections and predict severity.
Measures immune signatures for detecting and managing acute infections.
People of Inflammatix
Unlock access to complete
Unlock access to complete
Funding Insights of Inflammatix
Inflammatix has successfully raised a total of $191.47M across 13 strategic funding rounds. The most recent funding activity was a Series E round of $57 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inflammatix
Inflammatix has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, Khosla Ventures and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech & life sciences focused VC firm investing in geographies such as Europe
|
Locked | Locked | Locked | |
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked |
Investor details for Inflammatix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inflammatix
Investment portfolio details for Inflammatix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inflammatix
Detailed financials for Inflammatix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inflammatix Comparisons
Peer comparison for Inflammatix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inflammatix
Inflammatix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Karius, MeMed, Visby Medical, Agendia and GenMark Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Genomic diagnostic products for cancer treatment are provided.
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
Detailed competitors of Inflammatix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inflammatix
Complete news archive for Inflammatix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inflammatix
Inflammatix was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Inflammatix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Inflammatix is a funded company, having raised a total of $191.47M across 13 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Inflammatix is 54.
Inflammatix was founded in 2016 and is headquartered in San Francisco, United States. Operations focus on the health technology sector, where proprietary technology derived from Stanford University research is utilized. Gene expression patterns in the immune system are measured to diagnose sepsis and acute infections. Products offered include InSep for sepsis testing, ViraBac for infection differentiation, and SARS-CoV-2 swab tests.
Inflammatix's top competitors include Visby Medical, MeMed and GenMark Diagnostics.
Inflammatix offers TriVerity Test and Host Response Dx.
Inflammatix has 14 investors. Key investors include NIH, Khosla Ventures, HHS, DARPA, and OSF HealthCare.